Aurobindo receives FDA approval for vigabatrin tablets

Print Friendly, PDF & Email

EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application vigabatrin tablets USP, 500mg. Aurobindo Pharma’s vigabatrin tablets are an AB-rated generic equivalent to the reference listed drug (RLD), SABRIL tablets, manufactured by Lundbeck Pharmaceuticals LLC.

Vigabatrin tablets are indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures.

Vigabatrin tablets has an estimated market size of US $138 Million for the twelve months ending March 2022, as per IQVIA.



Comments are closed.